Q1 2026: Headline Numbers Set the Tone

Krystal Biotech (KRYS) opened 2026 with Q1 revenue of US$116.4 million and basic EPS of US$1.91. This put fresh numbers in front of investors who have been tracking its earnings ramp. The company reported quarterly revenue of US$88.2 million in Q1 2025 and US$116.4 million in Q1 2026, while basic EPS over the same quarters went from US$1.24 to US$1.91. This sets up a quarter where margins are front and center for anyone assessing the trajectory of the business.

See our full analysis for Krystal Biotech.

With the latest figures on the table, the next step is to weigh these margins and trends against the dominant market narratives around Krystal Biotech to see which views are backed by the data and which might need a rethink.

53.9% net margin sets a high bar

• On a trailing 12 month view, Krystal Biotech reported net income of US$225.0 million on US$417.3 million of revenue, which works out to a 53.9% net margin compared with 37.2% a year earlier.
• Bullish investors point to this high margin level, alongside trailing EPS of US$7.74 and 81.5% earnings growth over the past year, as lining up with their view that strong profitability can support bigger long term earnings power. Bears counter that any pressure on margins from higher R&D or commercialization costs would directly test that optimism.
  • Supporters of the bullish view highlight that margins above 50% and trailing revenue of US$417.3 million give the company a solid profit base to fund international expansion and pipeline work without relying only on external capital.
  • Skeptics focus on the risk section that flags rising general and administrative and R&D spending for global launches and multiple trials, arguing that if those costs rise faster than revenue, today’s 53.9% margin could move closer to the lower margin scenarios described in the bearish narrative.

Bulls argue these margins give the company more room to absorb future cost swings and still grow earnings power, while skeptics see them as a high watermark that could be hard to maintain as spending ramps. That tension is exactly what the detailed bull case walks through in more depth 🐂 Krystal Biotech Bull Case

Revenue ramp to US$417.3 million and earnings growth tension

• Over the trailing 12 months, revenue reached US$417.3 million with earnings of US$225.0 million, and that period included quarterly net income figures ranging from US$35.7 million in Q1 2025 to US$79.4 million in Q3 2025 before landing at US$55.9 million in Q1 2026.
• Bears argue that reliance on a single commercial therapy and variable patient treatment patterns can make these earnings swings hard to smooth out, and they see the wide range between high quarterly net income of US$79.4 million and the latest US$55.9 million as a sign that reported profit can shift quickly as patient starts, pauses and international ramp up move around.
  • The cautious narrative calls out that expanding into new indications and geographies requires heavy R&D and commercialization spending, and the quarterly net income path from US$35.7 million to US$79.4 million and then to US$55.9 million gives them support for the view that earnings may not follow a straight line even when the trailing 12 month growth looks strong.
  • At the same time, the 81.5% earnings growth over the past year and 63.3% 5 year earnings growth rate mean bears have to explain how that pace could slow enough for higher spending, pricing pressure and competition to bite into future profit levels despite the current revenue base.

Readers weighing that quarterly earnings pattern against the cautious narrative can see how much of the bearish case rests on how those revenue and cost lines interact over the next few years rather than on the trailing 12 month growth alone 🐻 Krystal Biotech Bear Case

P/E of 37.3x vs DCF fair value of US$806.36

• At a share price of US$284.57, Krystal Biotech is trading on a trailing P/E of 37.3x while the provided DCF fair value is US$806.36 and the single allowed analyst price target reference for this analysis is US$318.22. Investors are therefore comparing a premium earnings multiple with both a higher modelled cash flow value and a higher target level.
• For the bullish narrative, what stands out is that the DCF fair value and the 81.5% trailing earnings growth plus forecast earnings growth of about 21.1% a year are viewed as suggesting more upside than the current price reflects. The bearish side stresses that a 37.3x P/E, which is above peer and US biotech averages, leaves less room for disappointment if earnings growth or margins trend closer to their more cautious scenarios.
  • Supporters of the bullish view point to the combination of 53.9% trailing net margin, revenue of US$417.3 million and forecast revenue growth of roughly 19.9% a year as ingredients that they believe can justify the gap between the current price and the US$806.36 DCF fair value.
  • Critics highlight that the same 37.3x P/E multiple, when set against peer and industry levels, is consistent with the risk section that flags elevated valuation metrics, and they argue that if earnings growth trends toward the lower outcomes in the bearish narrative, the stock could be more sensitive to any shift in how the market prices that earnings stream.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Krystal Biotech on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of bullish and cautious views feels split, treat that as your prompt to look through the numbers yourself and decide what stands out. To see what is currently exciting optimistic investors, start with the 3 key rewards.

Explore Alternatives

Krystal Biotech combines high margins with a 37.3x P/E and earnings swings that leave some investors uneasy about paying up for that volatility and concentration risk.

If that mix of rich valuation and choppy earnings makes you cautious, it is worth checking stocks filtered through the 72 resilient stocks with low risk scores that focus on resilience and steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.